Severe cytokine release syndrome in a patient receiving PD‐1‐directed therapy
Pediatric Blood & Cancer2017Vol. 64(12)
Citations Over TimeTop 10% of 2017 papers
Abstract
Cytokine release syndrome (CRS) is a phenomenon of immune hyperactivation described in the setting of cellular and bispecific T-cell engaging immunotherapy. Checkpoint blockade using anti-programmed cell death 1 (anti-PD-1) inhibitors is an approach to antitumor immune system stimulation. A 29-year-old female with alveolar soft part sarcoma developed severe CRS after treatment with anti-PD-1 therapy. CRS was characterized by high fevers, encephalopathy, hypotension, hypoxia, hepatic dysfunction, and evidence of coagulopathy, and resolved after infusion of the interleukin-6 inhibitor tocilizumab and corticosteroids.
Related Papers
- → FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome(2018)865 cited
- → Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome(2020)28 cited
- → Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS(2016)25 cited
- → Role of Tocilizumab in the Treatment of COVID-19 Patients with Cytokine Storm: A Case Series(2022)2 cited